Head-to-head · Cost-Efficiency Index
G-Plans vs Omzo
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
G-Plans
Shoppers wanting a nutrition/genotype-assessment angle alongside optional GLP-1 access, willing to complete a quiz to see pricing.
Visit G-PlansOmzo
Cost-first shoppers who want not clearly assessable without pricing transparency; unsuitable to recommend confidently in a price comparison.
Visit OmzoThe verdict
G-Plans and Omzo tie on the Cost-Efficiency Index at 42/100, so neither wins outright on the numbers. For most shoppers we'd start with G-Plans (ranked #512, a hair above #514) — Shoppers wanting a nutrition/genotype-assessment angle alongside optional GLP-1 access, willing to complete a quiz to see pricing. But Omzo is a genuine coin-flip alternative here.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs G-Plans.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | G-Plans | Omzo |
|---|---|---|
| Cost-Efficiency Index | 42/100 | 42/100 |
| Semaglutide / mo | Not disclosed | Not disclosed |
| Tirzepatide / mo | Not disclosed | Not disclosed |
| Semaglutide / yr (modeled) | — | — |
| Tirzepatide / yr (modeled) | — | — |
| Coverage | Coverage not published | Coverage not published |
| Oral / sublingual | No | No |
| Brand-name access | Yes | Yes |
| Rank here | #512 | #514 |
G-Plans
42/100Where the value is
- LegitScript badge displayed
- Confirmed access to both branded (Ozempic) and compounded GLP-1 medications
- Distinctive nutrition-first / metabolic-genotype assessment angle vs. pure drug-dispensing competitors
The tradeoffs
- Zero pricing visible anywhere without completing the full intake quiz
- No named medical director or compounding pharmacy partner
Omzo
42/100Where the value is
- Broad multi-condition offering beyond weight loss (hormones, sexual health, skin, hair)
- States semaglutide and tirzepatide are both available
- Emphasizes licensed clinician review of every plan
The tradeoffs
- No pricing disclosed anywhere without completing a personal-data intake quiz
- No medical director named
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.